Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Itacitinib With Low-Dose Ruxolitinib or Itacitinib Alone After Ruxolitinib in Myelofibrosis
2017-005109-11Phase 2Terminated
- Sponsor
- Incyte
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of itacitinib in myelofibrosis (MF) (2 arms), sponsored by Incyte. Primary endpoints: Change in spleen volume at Week 24 and Percentage change in spleen volume at Week 24. Started Jun 2018; status: terminated.
02
Drugs
itacitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2017-005109-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005109-11.